MARC Record from marc_columbia

LEADER: 05049mam a2200289 a 4500
001 1712815
005 20220608215759.0
008 960319t19961996enka b 001 0 eng d
020 $a0127446400
035 $a(OCoLC)ocm34404181
035 $9ALB6106CU
035 $a1712815
040 $aGZM$cGZM$dOrLoB-B
245 04 $aThe Practice of medicinal chemistry /$cedited by Camille G. Wermuth.
260 $aLondon ;$aSan Diego :$bAcademic Press,$c[1996], ©1996.
300 $axvii, 968 pages :$billustrations ;$c25 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $g1.$tMedicinal chemistry: Definition and objectives. Drug and disease classifications /$rCamille G. Wermuth --$g2.$tDiscovering new drugs: the legacy of the past, present approaches, and hopes for the future /$rPhilippe Meyer --$g3.$tMeasurement and expression of drug effects /$rJean-Paul Kan --$g4.$tThe three main phases of drug activity: the pharmaceutical, the pharmacokinetic and the pharmacodynamic phases /$rCamille G. Wermuth --$g5.$tDrug targets - molecular mechanisms of drug action /$rJean-Pierre Gies --$g6.$tStrategies in the search for new lead compounds or original working hypotheses /$rCamille G. Wermuth --$g7.$tNatural products as pharmaceuticals and sources for lead structures /$rDavid G. I. Kingston --$g8.$tCombinatorial libraries and high-throughput synthesis /$rSheila Hobbs de Witt --$g9.$tSynthesis of peptide libraries for lead structure screening /$rVictor J. Hruby --$g10.$tThe contribution of molecular biology to drug discovery /$rAdrian N. Hobden --
505 80 $g11.$tElectronic screening: Lead finding from database mining /$rHans-Peter Weber --$g12.$tMolecular variations in homologous series: Vinylogues and benzologues /$rCamille G. Wermuth --$g13.$tMolecular variations based on isosteric replacements /$rCamille G. Wermuth --$g14.$tRing transformations /$rCamille G. Wermuth --$g15.$tIdentical and nonidentical twin drugs /$rJean-Jacques Bourguignon --$g16.$tApplication strategies for primary structure-activity relationship exploration /$rCamille G. Wermuth --$g17.$tSpecific substituent effects /$rCamille G. Wermuth --$g18.$tThe role of functional groups in drug-receptor interactions /$rPeter R. Andrews --$g19.$tQuantitative approaches to structure-activity relationships /$rHan van de Waterbeemd --$g20.$tStereochemical aspects of drug action I: Conformational restriction, steric hindrance and hydrophobic collapse /$rPhillip A. Hart and Daniel H. Rich --$g21.$tStereochemical aspects of drug action II: Optical isomerism /$rMiklos Simonyi and Gabor Maksay --
505 80 $g22.$tPharmacophore identification and receptor mapping /$rHans-Dieter Holtje --$g23.$tThree-dimensional quantitative structure-activity relationships: D[subscript 2] dopamine agonists as an example /$rYvonne Connolly Martin and C. Thomas Lin --$g24.$tThe use of X-ray structures of receptors and enzymes in drug discovery /$rJean-Michel Rondeau and Herman Schreuder --$g25.$tProtein homology modelling and drug discovery /$rMarcel F. Hibert --$g26.$tThe transition from agonist to antagonist activity: Symmetry and other considerations /$rDavid J. Triggle --$g27.$tDesign of peptidomimetics /$rHiroshi Nakanishi and Michael Kahn --$g28.$tThe fate of xenobiotics in living organisms /$rFrans M. Belpaire and Marc G. Bogaert --$g29.$tBiotransformation reactions /$rCamille G. Wermuth and Bernard Testa --$g30.$tChemical aspects of biotransformations leading to toxic metabolites /$rAndre Picot and Anne-Christine Macherey --
505 80 $g31.$tDesigning prodrugs and bioprecursors I: Carrier prodrugs /$rCamille G. Wermuth, Jean-Cyr Gaignault and Christian Marchandeau --$g32.$tDesigning prodrugs and bioprecursors II: Bioprecursor prodrugs /$rCamille G. Wermuth --$g33.$tMacromolecular carriers for drug targeting /$rEtienne H. Schacht, Stefan Vansteenkiste and Len Seymour --$g34.$tPreparation of water-soluble compounds through salt formation /$rBradley D. Anderson and Karl P. Flora --$g35.$tPreparation of water-soluble compounds by covalent attachment of solubilizing moieties /$rCamille G. Wermuth --$g36.$tDrug solubilization with organic solvents, or using micellar solutions or other colloidal dispersed systems /$rKurt H. Bauer --$g37.$tImprovement of drug properties by cyclodextrin /$rKaneto Uekama and Fumitoshi Hirayama --$g38.$tChemical and physicochemical solutions to formulation problems /$rCamille G. Wermuth --$g39.$tFrom discovery to market availability /$rJacques A. Dangoumau --$g40.$tDrug nomenclature /$rSabine Kopp-Kubel --
505 80 $g41.$tLegal aspects of product protection - what a medicinal chemist should know about patent protection /$rMaria Souleau --$g42.$tThe consumption and production of pharmaceuticals /$rBryan G. Reuben.
650 0 $aPharmaceutical chemistry.$0http://id.loc.gov/authorities/subjects/sh85023026
700 1 $aWermuth, C. G.$0http://id.loc.gov/authorities/names/n92800488
852 00 $bsci$hRS403$i.P73 1996g